Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics (NQ: CORT )

42.27 +2.56 (+6.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,547,000
Open 40.30
Bid (Size) 42.50 (1)
Ask (Size) 43.34 (1)
Prev. Close 39.71
Today's Range 40.15 - 43.32
52wk Range 20.84 - 41.95
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Via Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced. 
Via Chartmill

Performance

YTD
+74.96%
+74.96%
1 Month
+22.63%
+22.63%
3 Month
+50.16%
+50.16%
6 Month
+74.31%
+74.31%
1 Year
+30.79%
+30.79%

More News

Read More
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Via Chartmill
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
Unveiling 8 Analyst Insights On Corcept Therapeutics
Via Benzinga
6 Analysts Have This To Say About Corcept Therapeutics
Via Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
From Corcept Therapeutics Incorporated
Via GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Via Chartmill
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.